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Abstract The broad expression pattern of the G protein-
coupled P2Y receptors has demonstrated that these receptors
are fundamental determinants in many physiological
responses, including neuromodulation, vasodilation, inflam-
mation, and cell migration. P2Y receptors couple either Gq or
Gi upon activation, thereby activating different signaling
pathways. Ionotropic ATP (P2X) receptors bind extracellular
nucleotides, a signal which is transduced within the P2X
protein complex into a cation channel opening, which
usually leads to intracellular calcium concentration elevation.
As such, this family of proteins initiates or shapes several
cellular processes including synaptic transmission, gene
expression, proliferation, migration, and apoptosis. The
ever-growing range of applications for antibodies in the last
30 years attests to their major role in medicine and biological
research. Antibodies have been used as therapeutic tools in
cancer and inflammatory diseases, as diagnostic reagents
(flow cytometry, ELISA, and immunohistochemistry, to
name a few applications), and in widespread use in
biological research, including Western blot, immunoprecip-
itation, and ELISPOT. In this article, we will showcase
several of the advances that scientists around the world have
achieved using the line of antibodies developed at Alomone
Labs for P2Y and P2X receptors.
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P2Y receptors
P2Y receptors can be divided into two main subgroups: the
P2Y1 subfamily which comprises P2Y1,P 2 Y 2,P 2 Y 4,
P2Y6, and P2Y11 receptor subtypes. They all couple to
Gq, thereby activating phospholipase C. They are all
activated by various nucleotides, although P2Y11 is the
sole receptor specifically activated by ATP [1]. Various
cellular functions are attributed to these receptors in various
tissues and organs such as the brain, autonomic nervous
system, epithelia of the airway, gastrointestinal (GI) tract,
kidney, eye, vascular tissue, and the immune and inflam-
matory cells [1]. The second group, the P2Y12 subfamily,
includes the P2Y12, P2Y13, and P2Y14 receptors, which
share little homology with members of the P2Y1 subfamily
and are generally known to couple Gi.P 2 Y 12 and P2Y13 are
mostly activated by ADP, while P2Y14 is activated by
UDP-glucose and other nucleotide sugars. Signaling via the
latter is relatively in its early stage of understanding [1].
The P2Y12 receptor has an important role in platelets, is
highly expressed in the brain, and mediates microglia
migration in response to inflammation. P2Y13 is also
expressed in the brain as well as in the spleen. P2Y14 is
highly expressed in the brain, placenta, neutrophils,
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DOI 10.1007/s11302-011-9278-zlymphocytes, epithelial cells from various tissues, and in
the GI smooth muscle [1]. As new roles for these receptors
are continuously being unraveled and being that most
pharmacological tools available to study these receptors are
far from specific and mutually affect various receptors, the
use of specific antibodies has become essential to study
them. Alomone Labs offers specific polyclonal antibodies
targeted against all P2Y receptors, enabling the end user to
specifically detect the identity of the receptor in question.
We would like to emphasize that the use of antibodies is by
no means a replacement, but should be used in concert with
the pharmacological tools available. This short communi-
cation illustrates the purpose and the many advantages
using antibodies, specifically Alomone Labs antibodies,
have in researching purinergic signaling.
P2Y receptors in the CNS
Although extracellular purines may have both trophic and
apoptotic functions in the brain depending on the targeted
purine receptor and cell type, little is known about the role
of specific purine receptors in neurons [2]. It was shown
that both ADP and its stable analogue 2-methylthio-ADP
(2MeSADP) induced the upregulation of the cytoprotective
protein heme oxygenase-1 in rat cerebellar granule neurons.
Selective inhibition of 2MeSADP-responsive receptors
P2Y1 and P2Y13 and the use of pertussis toxin demonstrat-
ed a role of the purinergic P2Y13 receptor in this response.
Western blot analysis using anti-P2Y1 receptor (#APR-017)
and anti-P2Y13 receptor (#APR-017) antibodies confirmed
those results. These observations reveal a previously
unrecognized role in protection against oxidative stress by
extracellular purines acting on the metabotropic P2Y13
receptor and provide new perspectives for neuroprotective
therapies.
Microglial cells are the primary immune effector cells in
the brain. Extracellular ATP, e.g., released after brain injury,
may initiate microglial activation via the stimulation of
purinergic receptors. Amyotrophic lateral sclerosis (ALS) is
a progressive neurodegenerative disease characterized by
the selective loss of lower and upper motoneurons. The
pathology is imputable in ∼2% of cases to mutations in the
ubiquitous enzyme Cu,Zn superoxide dismutase (SOD1).
Common theories to explain the pathogenic mechanisms of
ALS include the activation of the microglia, responsible for
the release of pro-inflammatory factors. The effect of
mutant SOD1 on P2 receptor-mediated pro-inflammatory
microglial properties was investigated [3]. Primary and
immortalized microglial cells from mutant SOD1 mice were
used to explore several aspects of activation by purinergic
ligands and to analyze the overall effect of such stimulation
on the viability of NSC-34 and SH-SY5Y neuronal cell
lines. The upregulation of P2Y6 receptors (without changes
in P2Y2 and P2Y12 receptors) and the downregulation of
ATP-hydrolyzing activities in mutant SOD1 microglia were
observed using anti-P2Y6 receptor (#APR-006), anti-P2Y2
receptor (#APR-010), and anti-P2Y12 receptor antibodies in
Western blot analysis. The purinergic activation of the
microglia may thus constitute a new route involved in the
progression of ALS to be exploited to potentially halt the
disease.
The uridine nucleotide-activated P2Y2, P2Y4, and P2Y6
receptors are widely expressed in the brain and are involved
in many CNS processes, including those which malfunction
in Alzheimer’s disease (AD). However, the status of these
receptors in the AD neocortex, as well as their putative
roles in the pathogenesis of neuritic plaques and neurofi-
brillary tangles, remain unclear. In this study, Lai et al. [4]
used immunoblotting and immunohistochemistry using
anti-P2Y2 receptor, anti-P2Y4 receptor (#APR-006), and
anti-P2Y6 receptor antibodies in order to measure P2Y2,
P2Y4, and P2Y6 receptors, respectively, in two regions of
the postmortem neocortex of AD patients and aged
controls. P2Y2 immunoreactivity was found to be selec-
tively reduced in the AD parietal cortex, while P2Y4 and
P2Y6 levels were unchanged. In contrast, all three receptors
were preserved in the occipital cortex, which is known to
be minimally affected by AD neuropathology. Furthermore,
reductions in parietal P2Y2 immunoreactivity correlated
both with neuropathologic scores and markers of synapse
loss. These results provide a basis for considering P2Y2
receptor changes as a neurochemical substrate of AD and
point toward uridine nucleotide-activated P2Y receptors as
novel targets for disease-modifying AD pharmacotherapeu-
tic strategies.
In the CNS, P2 receptors are identified in neurons and
glial cells, mediating neuron–neuron, glia–glia, and glia–
neuron communication. Amadio et al. [5] qualified in vivo
in the adult rat CNS the cellular/subcellular distribution of
P2Y12 receptor in the cerebral cortex, white matter, and
subcortical nuclei (striatum and substantia nigra) by means
of electron microscopy, immunofluorescence, confocal, and
Western blot analysis using anti-P2Y12 receptor (#APR-
012) antibody. P2Y12 receptor immunoreactivity co-
localized only with myelin basic protein and the oligoden-
drocyte marker RIP in both cell bodies and processes,
indicating therefore oligodendrocyte localization. Since in
platelets the P2Y12 receptor is known to regulate adhesion/
activation and thrombus growth/stability, results from the
study presented helped speculate by analogy that, in
oligodendrocytes, P2Y12 receptor signaling might contrib-
ute to the migration and adhesion of the glial processes to
axons to be myelinated.
Apolloni et al. [6] established the direct toxic role and
anticancer activity of UDP in a neuroblastoma cell line SH-
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target in anti-tumoral therapies. This work investigated the
role of the P2Y6 receptor using anti-P2Y6 receptor antibody
in Western blot analysis and immunofluorescence micros-
copy. The in vitro results contribute to expand the general
knowledge about the P2Y6 receptor and to possibly identify
its manipulation as a strategy for the understanding and
potential relapse of neuroblastoma.
P2Y receptors in the spinal cord
Under normal conditions, pain is associated with electrical
activity in small-diameter fibers of dorsal root ganglions
(DRG) of the spinal cord. All subtypes of the P2Y receptor
family are widely expressed in different parts of the
nervous system. The activation of P2Y receptors causes
blockade of the N-type calcium channels in DRG cells.
This effect may decrease the release of glutamate from
DRG terminals in the spinal cord and thereby partly
counterbalance the algogenic effect of ATP released from
spinal cord nerve terminals upon depolarization and
probably from damaged or stressed cells upon pathological
conditions [7].
The involvement of P2Y receptors in the modulation of
rat spinal neurotransmitters glutamate and noradrenaline
release was investigated [7]. The study showed that the
inhibitory effect of ATP on glutamate release was mediated
by P2Y13 and/or by P2Y1 receptors, whereas the inhibition
of noradrenaline release was most likely mediated by P2Y13
and/or by P2Y1 and P2Y12 receptors. In order to explore the
cell type-specific distribution of the P2Y1 receptor and to
determine whether P2Y1 receptors, involved in the modu-
lation of glutamate release, are expressed on primary
afferent nerve terminals or interneurons, immunohisto-
chemical experiments were performed using anti-P2Y1
receptor antibody. Thus, the results indicated that sensory
information processing and its modulation by the descend-
ing noradrenergic pathway in the spinal cord could be
targeted by distinct subtypes of P2Y receptors, providing
novel sites of action for potential analgesic compounds.
Microglia in the spinal cord may play an important role
in the development and maintenance of neuropathic pain. In
spinal microglia, P2Y12 is expressed constitutively and is
involved in chemotaxis. The activation of p38 mitogen-
activated protein kinase (MAPK) occurs in spinal microglia
after nerve injury and may be related to the production of
cytokines and other mediators, resulting in neuropathic
pain. Anti-P2Y12 receptor antibody in immunohistochemi-
cal analysis of the dorsal horn cells 7 days after nerve injury
was used in order to demonstrate that the cells expressing
increased P2Y12 protein were exclusively microglia [8]. In
addition, the data suggested a new mechanism of neuro-
pathic pain in which the increased P2Y12 expression works
as a gateway in microglia following nerve injury. The
activation of this receptor by the released ATP activates the
p38 MAPK pathway and thus may play a crucial role in the
generation of neuropathic pain.
In another study, the expression and function in nociception
of P2Y1 and P2Y12 using their respective Alomone Labs
antibodies via immunohistochemistry analysis was examined
in sensory neurons [9]. The results demonstrated that
nociception sensitivity is modulated by the integration and
balance of nucleotide signaling through Gq-a n dG i-coupled
P2Y receptors which are altered in response to inflammatory
injury. Gi-coupled P2Y receptors are broadly expressed in
peripheral sensory neurons, inhibit nociceptive signaling, and
reduce behavioral hyperalgesia in vivo and thus represent
potential targets for the development of novel analgesic drugs.
On the other hand, P2Y1,aG q-coupled ADP receptor, is
required for the full expression of inflammatory hyperalgesia.
P2Y receptors in the ear
Purinergic signaling is inherently important to the hearing
organ and involves signal transduction via metabotropic G
protein-coupled P2Y receptors. Many of the principal
elements of the purinergic signaling complex have been
well characterized in the cochlea, forming the basis of
paracrine and autocrine communication systems in this
organ. The results presented below reinforce the signifi-
cance of extracellular nucleotide and nucleoside signaling
to hearing.
Huang et al. [10] used anti-P2Y2 receptor, anti-P2Y4
receptor, anti-P2Y6 receptor, and anti-P2Y12 receptor anti-
bodies in order to evaluate their expression during
development of the rat cochlea using immunohistochemis-
try analysis. The key findings of this study involved the
dynamic interplay between the expressions of the closely
related P2Y receptors mentioned above within the highly
differentiated cochlear tissue. None of the receptors
exhibited significant expression at the embryonic period
as P2Y receptor expression is pronounced in the developing
CNS. In the cochlea, neuronal P2Y receptor expression did
not commence until day 18 of the embryonic period.
During maturation of the hearing organ, P2Y receptor
expression became increasingly compartmentalized even to
a subcellular level in the case of the sensory hair cells and
some supporting cells.
The distribution of NTPDase5 and NTPDase6, two
intracellular members ofthe membrane-bound ectonucleoside
triphosphate diphosphohydrolases (E-NTPDase) family, in
the inner ear was investigated [11]. Their expression was
linked to the regulation of P2 receptor signaling in the adult
rat cochlea. By using anti-P2Y6 receptor and anti-P2Y14
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studies, it was found that noise-induced upregulation of
P2Y6 receptors in the spiral ganglion neurons further
supports the involvement of NTPDase5 in regulating P2Y
receptor signaling. Noise stress also induced P2Y14 receptor
expression in the root processes of the outer sulcus cells, but
this was not associated with the localization of the E-
NTPDases.
P2Y receptors in the eye
In the postnatal and mature retina, many processes are
controlled by the action of nucleotides. Their effects are
partly mediated via the activation of metabotropic P2Y
receptors. However, little is known about the developmen-
tal regulation and cellular localization of P2Y receptor
subtypes in the retina.
Immunohistochemical and neurophysiological methods
[12] demonstrated that purinergic signaling via P2Y1 and
P2Y4 receptors might contribute to differentiation processes
in the postnatal retina. Immunostaining adult rat retina for
P2Y2,P 2 Y 4,a n dP 2 Y 6 receptors showed that P2Y4
expression overlapped with the Müller cell marker, cellular
retinaldehyde-binding protein (CRALBP; Fig. 1). P2Y4 was
expressed predominantly in Müller cell end-feet (Fig. 1b).
Punctuate structures, forming a small band in the inner
plexiform layer (IPL), potentially representing synapses,
showed an intense staining for P2Y4, too. P2Y2 (Fig. 1a)
and P2Y6 (Fig. 1c) expression was largely restricted to
retinal neurons such as ganglion cells and cells of the inner
nuclear layer (INL). Immunohistochemical staining using
anti-P2Y4 receptor antibody showed indisputable expres-
sion of P2Y4, detectable only after the third postnatal week
(P20).
Intense neuronal activity in the sensory retina is
associated with a volume increase of neuronal cells and
a decrease in the osmolarity of the extracellular space
fluid. Wurm et al. [13] further showed the existence of an
endogenous purinergic mechanism that prevented hypo-
osmotic swelling of retinal glial (Müller) cells in mice.
They suggested that autocrine/paracrine activation of
purinergic receptors via UTP and enzymes is crucially
involved in the regulation of the glial cell volume. By
using anti-P2Y4 receptor antibody in immunohistochem-
istry experiments, they showed that P2Y4 immunolabeling
was localized to the somata of retinal neurons, but not
glial cells, while in other retinal layers, UTP may be more
directly involved in the regulation of glial cell volume, as
indicated by the co-localization of P2Y4 labeling and
CRALBP (Fig. 1d).
The expression of various P2Y receptor subtypes has
been demonstrated in the retina, but the localization of P2Y
receptors and their role in retinal signaling remain unclear.
The major findings of the study conducted by Ward et al.
[14] are that P2Y4 receptors are heavily expressed within
the inner retina, particularly within the dendrites and axon
terminals of rod bipolar cells and in cells postsynaptic to
cone bipolar cells, as demonstrated in Western blot and
immunocytochemistry methods using anti-P2Y4 receptor
antibody. Moreover, altering neural activity with light
altered P2Y4 expression within rod bipolar cell axon
terminals, and injection of the agonist UTP caused a
substantial reduction in the amplitude of the rod and cone
post-receptoral response (PII), indicating further evidence
for purines in retinal processing.
Detachment of the neural retina from the pigment
epithelium causes, in addition to photoreceptor deconstruc-
tion and neuronal cell remodeling, an activation of glial
cells. It has been suggested that gliosis contributes to the
impaired recovery of vision after reattachment surgery that
may involve both formerly detached and non-detached
retinal areas. Müller and microglial cell reactivity was
monitored in a porcine model of rhegmatogenous retinal
detachment to determine whether gliosis is present in
detached and non-detached retinal areas. The results
demonstrated that distinct symptoms of Müller cell gliosis
were not only restricted to the detached retinal areas but
occurred also in non-detached retinal regions of the surgical
eyes. Furthermore, among physiological changes, the
immunoreactivities for P2Y1 (Fig. 2, left panel) and P2Y2
(Fig. 2, middle panel), but not P2Y4 (Fig. 2, right panel)
receptor proteins, apparently increased only in detached
areas [15].
Extracellular ATP has been shown to mobilize intracel-
lular calcium in cultured ovine lens epithelial cells and in
human lens epithelium, suggesting a role for purines in the
modulation of lens transparency. The expression profiles of
P2Y receptor isoforms were characterized throughout the
rat lens at both the molecular and the functional levels [16].
The epithelium does not express P2Y1 and P2Y2, but the
underlying fiber cells, which differentiate from the epithe-
lial cells, exhibit strong membranous labeling. P2Y1
expression extended deeper into the lens compared with
P2Y2, and its expression co-localized with Cx50 gap
junction plaques, while P2Y2 did not. Immunohistochem-
istry using isoform-specific anti-P2Y4 receptor and anti-
P2Y6 receptor antibodies indicated that P2Y4 and P2Y6
receptors were observed in both epithelial cells and fiber
cells, but the labeling was predominantly cytoplasmic in
nature.TheinabilityofUTPandUDPtomobilizeintracellular
calcium in the epithelium and the predominantly cytoplasmic
location of P2Y4 and P2Y6 suggest that these receptors may
represent an inactive pool of receptors that may be activated
under non-physiological conditions. In contrast, their results
indicated that P2Y1 and P2Y2 a r ef u n c t i o n a l l ya c t i v ei nf i b e r
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suggest they may regulate distinct processes in the lens under
steady-state conditions.
P2Y receptors in the heart, cardiovascular and vascular
systems
Purinergic signaling has been shown to be important in the
cardiac and cardiovascular systems [17]. Presented are a
number of studies examining the functions of these
receptors in these vital systems.
Cardiac fibroblasts are a major cell type in the heart.
They have an important role in the functional and structural
aspects of the organ by secreting growth factors, cytokines,
and components of the extracellular matrix. During myo-
cardial infarction, ATP and ADP are released [18]. In
addition, various P2Y subtypes have been detected in rat
cardiac fibroblasts [19], and various studies indicate that
these receptors may play a role in cardiac function and may
be involved in the pathological processes of cardiac
diseases [20]. Cardiac fibroblasts are differentiated into
myofibroblasts which seem to play an important role in
myocardial infarction [21]. The differentiation of cardiac
Fig. 1 Expression of P2Y receptors in Müller cells of the adult rat and
mouse retinal slices. Immunohistochemical staining was accomplished
using anti-P2Y2 receptor (#APR-010) and anti-P2Y6 receptor (#APR-
011) antibodies. a No distinct immunoreactivity for the P2Y2 receptor
(red) was observed in Müller cells. However, ganglion cells (asterisk)
and structures within the inner plexiform layer (IPL), inner nuclear layer
(INL), and outer plexiform layer (OPL) display faint staining. b P2Y4
receptor (red) is highly expressed in Müller cell end-feet (arrows), as
detected using anti-P2Y4 receptor antibody (#APR-006). Additionally, a
band of globular structures, probably representing synapse of bipolar
cells in the ON-sublamina (ON) of the IPL, is stained for this receptor. c
The staining pattern of the P2Y6 receptor (red) is similar to that of P2Y2.
The insets in (b)a n d( c) show the ganglion cell layer (GCL)a n dt h eI N L ,
respectively, at higher magnification. ONL outer nuclear layer, OFF
OFF-sublamina of the IPL, PRS photoreceptor segments. Scale bars,
20 μm; inset scale bars,1 0μm. d Immunohistochemical staining was
carried out using anti-P2Y4 receptor antibody. The slices were co-stained
against the glial cell marker cellular retinaldehyde-binding protein
(CRALBP); co-labeling yielded a yellow-orange merge signal. Arrows,
Müller cell end-feet; arrowheads, Müller cell somata. GCL ganglion cell
layer, IPL inner plexiform layer, NFL nerve fiber layer, ONL outer
nuclear layer, PRS, photoreceptor segments. Scale bars,2 0μm. a–c
Adapted from reference 12 with permission of John Wiley and Sons. d
Adapted from reference 13 with permission of Wiley-Blackwell
Purinergic Signalling (2012) 8 (Suppl 1):S61–S79 S65fibroblast to myofibroblasts leads to the expression of
discoidin domain receptor 2 and α-smooth muscle actin.
Therefore, this cell type can be distinguished in part by the
expression of these proteins. Using a panel of Alomone
Labs anti-P2Y receptor antibodies, it was demonstrated that
P2Y1,P 2 Y 2,P 2 Y 4,P 2 Y 6,P 2 Y 11,a n dP 2 Y 13 are all
expressed by myofibroblasts and that all except for P2Y13
are also functional, as demonstrated by the use of
pharmacological agents [20]. Overall, the study shows that
the expression of different P2Y receptors which are
stimulated by different agonists suggests a complex
physiological role for these nucleotide receptors in regulat-
ing cardiac myofibroblast function in heart disease.
In the blood, integrins play an important role in
mediating the interaction between monocytes and epithelial
cells [22, 23]. In addition, integrins can also interact with
other proteins, leading to the activation of various signaling
pathways, many of which have an impact on many cellular
events [24]. The αVβ3 integrin influences cell signaling via
a plethora of receptors, including P2Y2 [25–27]. However,
the biological outcome of the interaction between P2Y2 and
αVβ3 integrin is not understood. The activation of P2Y2
receptors which are endogenously expressed in U037 cells
(monocytes) caused clustering of αV integrins, thereby
activating a signaling cascade involving the ERK1/2
MAPK pathway and cell migration [24]. The downregula-
tion of P2Y2 expression via shRNA abolished αV integrin
expression and concomitantly downstream signaling, as
demonstrated by Western blot analysis which showed that
both P2Y2 and αV integrin expression were downregulated
following treatment with their respective shRNA, but that
αV integrin shRNA had no effect on the expression of P2Y2
expression. The ability of P2Y2 to activate cell motility via
integrin activation may have important implications in
inflammatory processes and the treatment of inflammation
per se [24].
P2Y receptors in the gastrointestinal tract
and its surroundings
Purinoceptors play an important role in the regulation of the
GI tract motility. Reports show that P2 receptors modulate
relaxation of the GI tract [28], while others demonstrate that
they participate in the contraction [29]. These contradicting
results suggest that the contracting/relaxing activities of
purinergic receptors may be developmentally regulated.
Different approaches were used in order to verify this
hypothesis. Alomone Labs anti-P2Y1, P2Y2, P2Y4 receptor
antibodies were used to show that mostly P2Y1 and P2Y2
receptors are expressed, and the use of pharmacological
tools showed that P2Y1 mediates the relaxant response in
the GI tract from the first week after birth, whereas the
contractile activities observed shortly after birth decrease.
The transition from contraction to relaxation properties of
P2Y1 may be related to the cells which express the
receptors or to a change in the coupling to G proteins [28].
The nature of purinocetors was studied in the rat distal
colon since the neurotransmission input is usually non-
adrenergic and non-cholinergic [30]. Using Alomone Labs
anti-P2Y receptor antibodies in immunocytochemical studies
showed that various P2Y receptors are expressed in different
Fig. 2 Differential expression of P2Y receptors in glial following
retinal detachment. Immunohistochemical staining of control retinas
and from detached areas of porcine retinas 7 days after surgery was
done using anti-P2Y1 receptor (#APR-009), anti-P2Y2 receptor
(#APR-010), and anti-P2Y4 receptor (#APR-006) antibodies (red).
Immunoreactivities for P2Y1, P2Y2, and P2Y4 receptor proteins (red)
coincide with that of intermediate filament constituents vimentin
(green and yellow for merging signal). Arrows, vimentin-positive
fibers in the outer retina that were also stained for P2Y2 protein. GCL
ganglion cell layer, INL inner nuclear layer, IPL inner plexiform layer,
NFL nerve fiber layer, ONL outer nuclear layer. Scale bars,2 0μm.
Adapted from reference 15 with permission of Association for
Research in Vision and Ophthalmology
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specific since the pre-incubation of each antibody with its
respective peptide antigen abolished all immunoreactivity.
P2Y1 was co-localized with α-smooth actin, indicating that it
is expressed in vascular and enteric smooth muscle cells
(Fig. 3a). It also displayed a muscular localization, although
its expression did not overlap that of S-100. P2Y2 was
detected in myenteric neurons (Fig. 3b), P2Y4 was detected
in enteric glial cells (Fig. 3c), P2Y6 was shown to be
expressed in vascular and enteric smooth muscle cells
(Fig. 3d), P2Y11 in enteric glial cells (Fig. 3e), and P2Y12
was detected in enteric nerves (Fig. 3f). The study further
showed that more than one P2 receptor subtype is involved
in purinergic relaxation of the circular muscle of the rat distal
colon.
The duodenum secretes HCO3
− which is in part
responsible for protecting the upper GI tract from gastric
acid. Intestinal alkaline phosphatase (IAP) expressed along
the brush border has been shown to work at alkaline pH and
has an ATPase activity, although its exact function is
unknown. What is known, however, is that increased
secretion of HCO3
− by extracellular ATP enhances the
enzyme’s activity, suggesting a negative feedback loop. The
authors show that ATP is indeed a substrate for IAP activity
[31]. In addition, the inhibition of IAP leads to the release
of ATP, which activates purinergic receptors in the
Fig. 3 Expression of P2Y
receptors in rat distal colon. All
P2Y immunohistochemical
staining was done using
Alomone Labs anti-P2Y
receptor antibodies. a Double
immunolabeling reveals that
P2Y1 is expressed in enteric
smooth muscle cells and S100 in
enteric glial cells. b In the
myenteric plexus, P2Y2 is
detected in neurons. c P2Y4 is
detected in enteric glial cells. d
P2Y6 is expressed in vascular
and enteric smooth muscle cells.
e P2Y11 is detected in enteric
glial cells and P2Y12 is
expressed in enteric nerves (f).
Adapted from reference 30 with
permission of Elsevier
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−,
which in turn activates IAP, thereby decreasing ATP
concentrations and P2Y signaling. Immunofluorescence
studies using anti-P2Y1 receptor, anti-P2Y2 receptor, anti-
P2Y4 receptor, and anti-P2Y6 receptor antibodies showed
that P2Y1 receptors are expressed on the brush border
membranes of the duodenum (Fig. 4a). P2Y2 and P2Y4
expression were not observed (Fig. 4b, c), while that of
P2Y6 had a diffuse pattern of expression (Fig. 4d). The
receptors were also pharmacologically characterized such
that the activation of P2Y1 with ATP triggered an increase
in HCO3
− secretion, which was reduced by the addition of
P2Y1 antagonists.
P2Y receptors in other tissues and cells
Clara-like cells are epithelial cells present in the intra
pulmonary airways of various animal species and reside
near pulmonary neuroepithelial bodies (NEBs). They
demonstrate pluripotent stem cell-like features and are
mainly involved in airway epithelial regeneration following
lung injury [32–34]. NEBs are clusters of pulmonary
neuroendocrine cells and have been suggested to have a
role in various physiological processes in the lungs, with a
significant role in airway oxygen sensing [35, 36].
Purinergic signaling in NEBs has only been indirectly
demonstrated by ATP accumulation in secretory vesicles of
rat NEBs [37]. In order to understand the possible cross talk
between NEBs and Clara-like cells, the hypothesis that ATP
acts as a paracrine transmitter in the NEB microenviron-
ment was tested. Calcium imaging, pharmacology, and
immunohistochemistry (using Alomone Labs antibodies)
were all employed to identify and localize purinoceptors
[33]. Clara-like cells were shown to express functional
P2Y2 receptors. The study further shows that the two cell
types are indeed coupled by the release of ATP by NEB
cells and the subsequent activation of purinoceptors (P2Y2)
localized on the membranes of Clara-like cells. This
signaling pathway may be essential for normal airway
function, for the regeneration of airway epithelial following
injury, and also perhaps for the pathogenesis of small cell
carcinomas [33].
P2Y receptors in disease states
Hepatocytes express receptors for high-density lipoprotein
(HDL) which are responsible for carrying cholesterol from
peripheral tissues to the liver for elimination. Studies show
that HDL levels are inversely proportional to the risk of
developing coronary artery disease [38]. In hepatocytes,
HDL undergoes endocytosis in a P2Y13-dependent manner
[38–40]. The signaling pathway leading from P2Y13 activa-
tion to the internalization of HDL was examined. The study
shows that P2Y13 stimulation specifically induced RhoA
activation and its effector ROCK I, leading to HDL
endocytosis through cytoskeleton reorganization. P2Y13
silencing via shRNA, which was demonstrated by both a
decrease in mRNA levels and protein levels (as shown by
Western blot analysis using anti-P2Y13 receptor antibody),
prevented the membrane translocation of ROCK I induced
by known P2Y13 agonists. Deciphering new molecular
targets involved in HDL endocytosis may be important for
Fig. 4 Expression of P2Y
receptors in rat duodenal
epithelium. Immunohistochemical
staining was done using anti-P2Y1
receptor antibody (#APR-009),
anti-P2Y2 receptor antibody
(#APR-010), and anti-P2Y6
receptor antibody (#APR-011). a
P2Y1 is expressed along the brush
border membranes of
villous cells. P2Y2 and P2Y4
receptors are not expressed (b, c).
d P2Y6 receptor is diffusely
expressed in the villous cells and
interstitium. Adapted from refer-
ence 31 with permission of John
Wiley and Sons
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cholesterol transport [38].
Low-intensity pulsed ultrasound (LIPUS) is a noninva-
sive technique used to stimulate the healing process of bone
fractures. The only known molecular event involved in
LIPUS treatment is the release of purines from osteoblasts.
P2 receptors were pharmacologically detected in osteo-
blasts. Activation was monitored by calcium mobilization
which was abolished upon the addition of inhibitors of
endoplasmic reticulum calcium release. Although all P2Y
receptor subtypes tested were detected in indirect flow
cytometry experiments using their respective Alomone
Labs antibodies (Fig. 5), P2Y1 seems to have a prominent
role upon LIPUS treatment as inhibitors of this receptor
abolished the proliferation of osteoblasts [41].
Melanoma is a tumor originating from melanocyte.
These tumors express P2Y1 and P2Y2 receptors, among
others [42]. Immunocompromised mice were injected with
melanoma cells, and the role of purinergic agonists on
tumor size and development was examined. Following ATP
administration, the tumors had a necrotic appearance.
Immunohistochemistry studies using Alomone Labs anti-
bodies showed that the expression of P2Y1 increased in the
areas adjacent to the necrotic region, strongly suggesting
that ATP can be used as a treatment for melanoma.
Achondroplasia is a pathology causing dwarfism. It is
caused by a mutation in the fibroblast growth factor
receptor 3 (FGFR3) gene, leading to the constitutive
activation of the FGFR3 signaling pathway. In addition,
the mutant form of the receptor is unable to mobilize
calcium, suggesting that calcium mobilization (or lack of)
plays a role in the development of the pathology. P2Y
receptors have been described in chondrocytes (cells in the
endochondral bone growth in mammals) [43]; however,
their presence and function in achondroplastic chondrocytes
have been examined in the presented study [44]. Using
confocal microscopy, immunoreactivity against P2Y1,
P2Y2, P2Y6, and P2Y11 was detected using Alomone Labs
antibodies, while that of P2Y4 was not present in
achondroplastic chondrocytes. The results were also con-
firmed by Western blot analysis. Treating these cells with
dinucleotide polyphosphates gave rise to an increase in
intracellular calcium concentrations. This effect was elim-
inated (to various extents) by applying different P2
antagonists. Treating chondrocytes with FGF9, the natural
ligand of FGFR3, promoted calcium mobilization which
was not observed when treating achondroplastic condro-
cytes with the same ligand, due to the constitutively active
FGFR3 signaling cascade. However, when treating these
cells with dinucleotide polyphosphates prior to FGF9
treatment, the calcium mobilization was restored by a
mechanism that is yet still not understood. The study
suggests that the activation of P2Y receptors may be a
useful pharmacological tool to reset the modified biochem-
ical process observed in achondroplasia.
In the next section, we discuss the many uses of our
antibodies directed against ionotropic P2X receptors.
P2X receptors
The P2X receptors are a family of ligand-gated, non-
selective cation channels that open in response to extracel-
lular ATP. In vertebrates, the family comprises seven
members termed P2X1–P2X7 that share 40–50% sequence
homology. The P2X receptors have a topology that includes
Fig. 5 Expression of P2Y receptors in osteoblasts. Using flow
cytometry analysis, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, and
P2Y13 receptors were detected in osteoblasts using their respective
Alomone Labs antibodies (open histograms). Incubating the antibody
with the control peptide antigen was used as a negative control (filled
histograms). Adapted from reference 41 with permission of Elsevier
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lular domain, and intracellular N- and C-termini. Their
functional subunit is a trimer, and they can form either a
homomeric unit (with the exception of P2X6) or hetero-
trimers with other P2X subunits which display properties
that differ from the corresponding homomeric form. The
P2X receptors play key roles in various physiological
processes such as nerve transmission, pain sensation, and
immune response [45], but open questions, with important
physiological and pharmaceutical implications, still exist in
this expanding field of research [46].
Alomone Labs invests great efforts in the development of
antibodies that are tailored to the needs of the research
community. Our antibody development process begins with a
deepunderstandingofthe structure,biology,andfunctionality
of each and any one of the receptors and channels against
which we prepare the antibodies. Our antibodies are prepared
using a peptide chosen from the sequence of each one of the
channels that is thoroughly examined to preclude cross-
reactivity first of all with other members of the close channel
family and then with other known non-related proteins. Our
antibodies are always affinity purified in order to provide the
best possible specific antibody content and avoid as much as
possible unwanted non-relevant antibodies in the final
antibody preparation. In addition, our antibodies are always
rigorously tested in a Western blot assay in the appropriate
target tissues to confirm functionality.
Below, we have summarized for each P2X isoform
recent literature citing the use of Alomone Labs anti-P2X
receptor antibodies and the contribution of these works to
our understanding of the roles played by P2X receptor
channels in several physiological and pathophysiological
processes. Due to space constrictions, only a handful of
these contributions will be acknowledged, and we regret
any inconvenience that this may arise.
P2X1
P2X1 is relatively widely expressed with prominent
expression in platelets, megakaryocytes, smooth muscles,
and vas deferens.
P2X1 is the sole P2X receptor present in platelets, and
the activation of the receptor generates an increase in
intracellular Ca
2+, which in turn leads to the secretion of
secretory granules and shape change [45, 47]. Indeed, using
Alomone Labs anti-P2X1 receptor antibody (#APR-001),
Vial et al. [48] showed the co-localization of P2X1 with
CD41, a known marker of platelets and megakaryocytes, in
samples obtained from bone marrow and spleen (Fig. 6, top
panels). P2X1 platelet localization in human platelets was
confirmed later by several groups using the anti-P2X1
receptor antibody [49, 50].
It is now widely recognized that P2X1 has a key role in
platelet function. For instance, it has been shown that the
Fig. 6 Co-localization of P2X1 and CD41 in bone marrow (top panel)
and double immunofluorescence for P2X2R channel and orexin in
hypothalamic neurons (bottom panel). Top panel, P2X1 receptor
immunoreactivity (red, #APR-001) is co-localized with CD41 (green).
Similar levels of immunoreactivity were detected in tissues from 5-
day-old (left two images) and adult mice (right two images). Bottom
panel, P2X2R channel staining (red, #APR-003) (a); orexin staining
(green)( b); merge (c). Note that some P2X2R-labeled cells do not
stain for orexin (arrows). f fornix. Top panels; adapted from reference
48 with permission of John Wiley and Sons (a–c). Adapted from
reference 55 with permission of John Wiley and Sons
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known platelet activators, such as thrombin and collagen, to
increase platelet aggregation. Indeed, the importance of
P2X1 activation in platelets seems particularly important
under conditions of high shear stress, suggesting that P2X1
is an attractive antithrombotic target [47].
P2X1 receptors have a key role as neurotransmitter
receptors at sympathetically innervated smooth muscle cells
in urinary bladder, vascular smooth muscle cells, and
skeletal muscle, among others. Indeed, the localization of
P2X1 in rat pulmonary artery smooth muscle cells and
human skeletal muscle cells was demonstrated using anti-
P2X1 receptor antibody [51, 52].
The localization of P2X1 receptor in afferent arteriole
vascular smooth muscle cells is of particular importance as
it demonstrates a critical role for this receptor in renal
autoregulation, a process by which the kidney is able to
maintain constant renal blood flow and glomerular filtration
rate over changes in arterial pressure. Zhao et al. [53] nicely
showed P2X1 immunoreactivity on the vascular smooth
muscle cells of microdissected renal interlobular artery and
afferent arteriole using anti-P2X1 receptor antibody.
P2X2
The P2X2 channel is mostly expressed in the central and
peripheral nervous system with predominant expression in
dorsal ganglia neurons, mesenteric ganglia neurons, taste
buds, and astrocytes and plays a key role in synaptic
transmission, pain, and taste perception.
Indeed, using anti-P2X2 receptor antibody (#APR-003),
Ohta et al. [54] showed the localization of P2X2 in rat
cultured myenteric neurons, implying that purinergic
signaling is involved in the regulation of GI functions.
Similarly, Florenzano et al. [55] demonstrated the co-
localization of P2X2 with orexin in hypothalamic neurons,
suggesting that P2X2 may be involved in arousal and
wakefulness (Fig. 7a–c).
The involvement of P2X2 in taste transduction was
demonstrated by showing the localization of P2X2 in taste
buds using Alomone Labs’ respective antibody [56]. P2X2
forms functional heteromers with P2X3 channels, and the
P2X2/P2X3 unit has been described as a major player in
pain transmission (see also below). Using anti-P2X2
receptor antibody, the presence of the receptor was
demonstrated in rat dissociated DRG neurons from normal
and inflamed animals [57].
P2X3
P2X3 and P2X2/P2X3 receptors are selectively localized on
sensory neurons in trigeminal, nodose, and DRG. P2X3
receptors are now recognized as major players in mediating
the primary sensory effects of ATP and, as such, are of
major importance in nociception and mechanosensory
transduction. Hence, P2X3 and P2X2/P2X3 represent
unique targets for novel analgesic agents that function as
receptor antagonists [58].
Current theories predict that chronic pain is brought
about by a gain in the expression and function of sensory
nociceptors that enhance their signal flow to the brain to
ensure the long-lasting nature of this process. In this regard,
both P2X3 and P2X2/P2X3 receptors were found to be
modulated by several other receptors and ion channels
known to be involved in pain perception. For instance, a
selective, slow upregulation of nociceptive P2X3 receptors
on trigeminal neurons by the neuropeptide calcitonin gene-
related peptide, a known endogenous pain mediator, was
demonstrated using anti-P2X3 receptor antibody (#APR-
016) [59]. Similarly, using anti-P2X3 receptor and anti-
P2X2 receptor antibodies, it was shown that the neutraliza-
tion of endogenous nerve growth factor, another key pain
transmission molecule, decreased P2X3 receptor-mediated
currents and enhanced the expression of P2X2 subunits by
P2X3-immunoreactive neurons [60].
In addition, using Alomone Labs antibodies in immu-
nohistochemical studies, Banerjee et al. [61] showed that
P2X3 exhibited a significant upregulation both in DRGs
and in nodose ganglia of rats having chronic esophagitis,
suggesting that the upregulation of P2X3 receptors in
sensory neurons following inflammation may contribute to
altered sensation from the esophagus (Fig. 7a).
P2X4, P2X5, and P2X6
P2X4 is widely expressed in many neuronal and non-
neuronal tissues. Localization studies at both protein and
mRNA levels have demonstrated a wide expression pattern
for the P2X4 channel: rat brain, kidney, lung, heart, spinal
cord, and more were shown to express the receptor [62].
Although its role in most of these tissues remains elusive,
due to the lack of highly specific antagonist, recent studies
suggest an important role for P2X4 in chronic inflammation
and neuropathic pain by spinal cord microglia. Following
spinal cord injury or peripheral nerve injury, the upregula-
tion of P2X4 receptor in activated microglia was detected.
Partial nerve injury (PNI) induced a restricted de novo
expression of P2X4 by activated microglia. Immunohisto-
chemical staining, comparing P2X4 expression in the spinal
cord of sham-operated mice versus PNI mice using the
specific anti-P2X4 receptor antibody (#APR-002), indicated
that sham-operated mice expressed low, barely detectable
levels of P2X4, while PNI mice, 10 days following the
injury, expressed significant levels of P2X4 (Fig. 7b, c)
[63]. It seems that the activation of the microglia following
nerve injury is not mediated by P2X4 since the activation of
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−/− mice was not affected
[63]. However, in P2X4
−/− mice with spared nerve injury
(neuropathic pain model), tactile allodynia was significantly
reduced compared with wild-type mice, indicating a
possible role for P2X4 in chronic pain [63].
Apart from their importance as a tool in proteomics
studies by identifying protein expression, tissue distribu-
tion, and more, antibodies can also be used as a tool for
determining structural and functional interaction. Assembly
and trafficking of the P2X4 and P2X7 channels were
demonstrated in microglia cells prepared from cerebral
cortices of newborn rats using anti-P2X4 receptor and anti-
P2X7 receptor (#APR-004) antibodies [64]. Using cross-
linking agents, biotinylation technique, Blue native PAGE,
and specific antibodies, it was demonstrated that in primary
cultures of rat microglia, P2X4 and P2X7 receptors
preferentially assemble as homotrimers [64]. Analysis of
P2X4 and P2X7 expression on the plasma membrane of
primary microglia cells indicated that P2X4 resides pre-
dominantly within intracellular compartments, while P2X7
showed a prominent expression at the plasma membrane.
The activation of the microglia with lipopolysaccharide
increased the stability of P2X4 expression on the plasma
membrane within 3 h post-stimuli followed by a modest
increase in the overall expression of the channel, as
demonstrated by Western blot analysis.
The use of subunit-specific antibodies enables the
detection of the different P2X subunits in tissues as well
as in primary cultures or cell lines. In rat cultured cortical
astroglia, immunohistochemical studies demonstrated that
Fig. 7 Distribution pattern of
P2X3 immunoreactivity in
peptidergic and non-peptidergic
small-diameter c-fibers in dorsal
root ganglion (DRG) and nodose
ganglion (NG) neurons.
Expression of P2X4 in activated
spinal microglia following
peripheral nerve injury (PNI). a
DRG sections were stained with
P2X3 (red, #APR-016) and
substance P (SP, green)
antibodies (upper panel) or with
P2X3 (red) and isolectin-B4
(IB4, green) antibodies (lower
panel). Pink arrows indicate
P2X3-positive cells with IB4 or
SP immunostaining, and white
arrows indicate P2X3-positive
cells without IB4 or SP binding.
b Immunohistochemical staining
comparing P2X4 expression in
sham and injured mice using
anti-P2X4 receptor antibody
(#APR-002, green). P2X4
expression was barely detectable
in sham animals, whereas
10 days post-PNI, it was
upregulated ipsilateral to the
lesion. Scale bar, 500 μm. c
P2X4 expression (red)i n
activated microglia following
peripheral nerve injury is
co-localized with microglia-
specific eGFP fluorescence in
CX3CR1
+/GFP mice 10 days
post-PNI. Scale bar, 100 μm.
a Adapted from reference 61
with permission of Springer.
b–c Adapted from reference 63
with permission of Society for
Neuroscience
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express multiple P2X receptors, predominantly the P2X4,
P2X6, and P2X7 (using anti-P2X4 receptor, anti-P2X6
receptor (#APR-013), and anti-P2X7 receptor antibodies)
as well as P2Y receptors. Although expressing both P2X
and P2Y receptors, it was demonstrated that P2Y1 and
P2Y2 receptors are involved in calcium signaling in
response to extracellular nucleotides, thereby playing a role
in cell-to-cell signaling (Fig. 8)[ 65].
Lacking specific antagonists to the P2X4 channel, P2X4
−/−
knockout (KO) mice were used to elucidate the role of P2X4
in hippocampal synaptic transmission. KO of P2X4 was
assessed by Western blot analysis [66]. It was demon-
strated that P2X4 in wild-type animals affects long-term
potentiation, an effect which was abolished in the KO
animals [66].
In a study, testing the effect of different external ionic
environments on calcium changes and the expression of
P2X purinergic receptors in control and cystic fibrosis
airway epithelial cells, it was demonstrated that CFBE41o−
airway epithelial cells express P2X4, P2X5, as well as P2X6
by immunohistochemical studies using anti-P2X4 receptor,
Fig. 8 Localization of P2X receptor subunits on astroglia. Localization
of P2X receptors in astroglia was characterized by double immunoflu-
orescence staining of P2X1 (A), P2X2 (B), P2X3 (C), P2X4 (D), P2X5
(E), P2X6 (F), P2X7 (G) using their respective Alomone Labs antibodies
(Cy3, red) and GFAP (Cy2, yellow green). Strong staining for the P2X1
receptor was detected only in axon-like fibers (A). No clear immuno-
reactivity was observed for P2X2 and P2X3 receptor subtypes on
astroglia (B, C). P2X4,P 2 X 5,P 2 X 6,P 2 X 7 receptors were found to be
expressed (Da, Ec, Fa, Ga). As representative control images are the
anti-P2X5 receptor antibody (#APR-005) pre-incubated with its control
peptide antigen (Ea) and GFAP fluorescence alone (Ea–d). Adapted
from reference 65 with permission of Elsevier
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antibodies [67].
P2X7
Once cloned from rat brain, P2X7 was described as the P2Z
receptor which is responsible for the ATP-dependent lysis of
macrophages through the formation of membrane pores
permeable to large molecules and could function also in fast
synaptic transmission as a calcium-permeable cation channel
[68].
P2X7 channels are reported to be functionally expressed
in several types of lymphocytes in which they mediate
responses to high extracellular ATP, especially programmed
cell death and cytokine secretion. In addition, P2X7
channels are expressed in macrophages and the related
brain microglia, where they mediate activation and prolif-
eration and therefore are central players in immunogenic
responses to inflammation. P2X7 are probably expressed in
neurons where they function both as classical ligand-gated
ion channels and as mediators of programmed cell death in
response to environmental signals.
The central role played by P2X7 channels in responses of
the immune system have placed it as a promising drug
candidate to treat immune system-derived conditions. In
such a case, the exact expression pattern and the exact
function of the receptor in each tissue are necessary for
drug development as a risk assessment. This is the point
where specific antibodies, specific pharmacology, and KO
techniques are valuable experimental tools.
Alomone Labs has generated two anti-P2X7 receptor
antibodies, one intracellular (#APR-004 and its ATTO-550
fluorescent-labeled version, #APR-004-AO), targeting the
P2X7 C-terminal, which is unique among the family of P2X
receptors, and a different antibody, anti-P2X7 receptor
(extracellular) targeting an epitope on the extracellular
moiety of the channel (#APR-008 and its FITC-
conjugated version, #APR-008-F). The design of two
different antibodies was of particular importance as the
P2X7 channel is encoded by a multi-exon gene and
therefore different splice variants of the protein may exist.
Both antibodies recognize in Western blot analysis and
immunocytochemistry P2X7-transfected cells versus the
untransfected counterpart in several different systems such
as HEK cells, Xenopus oocytes, etc. [69–74].
The lack of P2X7 expression in KO mice was confirmed
using Alomone Labs antibodies in Western blot or
immunohistochemistry analyses in the following tissues:
salivary gland [73], lung [73], tymocytes [75], peritoneal
macrophages [76], bone marrow-derived macrophages [64],
microglia [64], astroglia [77], retina [78], ependymal cells
along the lateral ventricle of the mouse brain [79], and
calvarial osteoblasts (skull bone cells) [80].
In several other tissues, P2X7 immunoreactivity was
seen also in KO mice; these include: brain [73, 76] (and see
early discussion in [81]), splenic follicles and lymph node
[82], and spleen [73]. However, some of these observations
were accompanied by the discovery of a novel P2X7 splice
variant which was not knocked out by the KO procedure
and its mRNAwas detected in many tissues including brain
[73] or by the notion that lymphocytes from KO mice
exhibit enhanced P2X7 responses [82].
P2X7 in the immune system
In mouse T lymphocytes, P2X7 expression was assessed by
anti-P2X7 receptor (extracellular) antibody in immunohis-
tochemical studies on splenic follicles and by Western blot
analysis of lymph node [82]. It is worth mentioning that in
that particular study, Taylor et al. discovered an enhanced
P2X7 activity in lymphocytes from KO mice, which was
accompanied by the detection of P2X7 expression in these
gene-targeted mice. P2X7 was also detected differentially
by Western blot analysis in spleens of wild-type versus KO
mice [73], which also demonstrated that a functional P2X7
splice variant with an alternative transmembrane domain 1
escaping gene inactivation in P2X7 KO mice.
In mouse tymocytes, P2X7 receptors mediate ATP-
dependent non-selective pore formation and cell death.
The receptor expression in these cells (from two mouse
strains) was confirmed by Western blot analysis with the
intracellular antibody and a comparison to parallel cells
from P2X7 KO mice in which expression was not detected
[75]. The main pathway of P2X7R-mediated thymocyte
death was necrosis/lysis rather than apoptosis.
Using anti-P2X7 receptor and anti-P2X7 receptor (extra-
cellular) antibodies, it was shown by Western blot analysis
that the expression of P2X7 receptors in peritoneal macro-
phages from control mice is totally absent in similar
preparations from KO mice [76]. By using the intracellular
antibody in FACS analysis in the same cell type, the
expression of the channel was demonstrated. Regarding
modulation of the receptor’s activity in relation to cell
death, it was shown that nucleoside triphosphate diphos-
phohydrolase 1 (NTPDase1)/CD39 (which is the dominant
ectonucleotidase expressed by murine peritoneal macro-
phages) protects peritoneal macrophages from ATP-induced
death via the suppression of P2X7 activation by high
extracellular ATP [83]. Co-immunoprecipitation experi-
ments in these cells demonstrated that following activation
with a “danger signal,” Biglycan, a ubiquitous leucine-rich
repeat proteoglycan of the extracellular matrix, P2X7
receptors interact with TLR2/4 in wild-type but not in KO
mice to activate interleukin 1β secretion [84].
In experiments that ruled out the expression of P2X7 in
human neutrophils, the mouse macrophage cell line J774
S74 Purinergic Signalling (2012) 8 (Suppl 1):S61–S79was used as a positive control, and indeed, P2X7 expression
was demonstrated by Western blot analysis with both the
intracellular and extracellular antibodies. In addition,
immunocytochemistry with anti-P2X7 receptor (extracellu-
lar)-FITC demonstrated P2X7 membrane expression in
living J744 cells [72].
P2X7 in the CNS
Although P2X7 is clearly expressed in brain tissue, the
question whether its expression is restricted to non-neuronal
cells is a matter of ongoing debate (see below).
In ependymal cells along the lateral ventricle of the
mouse brain, P2X7 immunoreactivity was observed in brain
slices, which was absent in KO mice. Using gold labeling
and electron micrographs, it was shown that P2X7 is
expressed in the plasma membrane of an ependymal cell
specifically localized on the surface of the cilia and
microvilli of these barrier cells [79].
Western blot analysis of mouse microglial cells (as well
as in macrophages) showed that P2X7 is highly expressed
in control, but not in KO mice preparations. In addition,
using immunoprecipitation methods, it was revealed that
homotrimers of P2X7 were able to co-immunoprecipitate
with P2X4, suggesting that an interaction occurs between
rather than within receptor complexes. P2X7 receptors were
predominantly at the cell surface, whereas P2X4 receptors
were predominantly intracellular [64].
Several splice variants of P2X7 were discovered and
characterized to a certain extent, but in most cases, their
differential functions, physiological roles, and localization are
still a matter of research. However, the availability of two
antibodies directed against different domains of the channel
may serve as a tool for detecting the differential localization
of these splice isoforms. Western blot analysis of lysates from
astrocytes in cultures originating from either the cortex or the
hippocampus revealed the possible presence of different
isoforms of the P2X7 receptor in astrocytes cultured from
distinct brain regions. Anti-P2X7 receptor antibody detected
the presence of a protein band of the predicted molecular
weight of 66 kDa in both hippocampal and cortical
astrocytes. The presence of a band corresponding to the
full-length receptor in both astrocyte cultures was confirmed
by the anti-P2X7 receptor (extracellular) antibody. This
antibody recognized in the hippocampal, but not in cortical
cultures, a major band of about 27 kDa, likely corresponding
to a cytoplasmic tail-deleted variant of the receptor, given it
was not detected by the anti-P2X7 receptor antibody [85].
In cortex–striatum–subventricular zone organotypic cul-
tures, anti-P2X7 receptor antibody in immunocytochemistry
studies was used to show that P2X7 expression is upregu-
lated and that its staining is co-localized with microglial
marker OX42 following 40 min of oxygen and glucose
deprivation (OGD) [86]. This upregulation contributes to
microglia activation and the following neuronal damage. A
similar upregulation was evaluated in the mouse N9 micro-
glial cell line, as seen in Western blot, following OGD [86].
By performing immunohistochemistry on spinal cord
preparations and Western blot analysis on spinal cord
microglial cell lysates of rats receiving morphine, P2X7
immunoreactivity was co-localized with the microglial
marker OX42, but not the astrocytic marker GFAP, in the
spinal cord. The protein level of spinal P2X7R was
upregulated after chronic exposure to morphine and
contributed to the generation of tolerance (Fig. 9)[ 87].
Whether the P2X7 receptor is expressed in neurons
remains controversial. One of the main reasons for this
ongoing debate arises from the fact that P2X7 immunore-
Fig. 9 Double immunostaining of P2X7R and cell-specific markers in
morphine-tolerated rats. a Schematic diagram of the spinal cord. Black
open square (a) marks the corresponding scope of confocal images (b,
d) on the spinal cord section. White open squares (b, d) mark the
corresponding scope of amplified images (c, e) on the confocal
images. b, c Double immunostaining of P2X7R and the microglial
marker OX42. d, e Double immunostaining of P2X7R and the
astrocytic marker GFAP. Scale bars,4 0μm( b, d)a n d1 0μm( c, e).
Adapted from reference 87 with permission of Society for
Neuroscience
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P2X7 KO mice. For example, two bands of 65 and 77 kDa
are detected in Western blot analysis using anti-P2X7
receptor antibody in the wild-type mouse whole brain,
which is maintained in brains from KO animals, while the
single 77-kDa band that is detected in peritoneal macro-
phages of wild-type animals is abolished by the KO [76]. In
addition, P2X7 immunoreactivity which is detected on
cerebellar granule cells from wild-type mice in culture is
seen also in such cells from KO animals.
P2X7 is expressed in the developing rat brain from
embryonic day 14 and might be involved in programmed
cell death during embryogenesis. Immunoreactivity of the
P2X7 receptor protein in the developing brain was detected
in the lateral hypothalamus at E14, the lateral olfactory tract
and optic tract and in the cerebellum, midbrain, and
medulla at E18 [88].
P2X7 was also detected by Western blot analysis in rat
primary cortical neurons in culture, which were confirmed
as such by positive staining with monoclonal antibody
against the neuronal marker NeuN. The P2X7 positive
signal was reduced once the cells were treated with a
specific antisense oligonucleotide. Functional studies with
specific pharmacology have suggested that extracellular
ATP mediates neuronal apoptosis through the activation of
the P2X7 receptor and its downstream signaling pathways
involving JNK1, ERK, and caspases 8/9/3 [71].
P2X7 expression and role in other tissues
The expression of P2X7 was confirmed in calvarial
osteoblasts (skull bone cells) in Western blot analysis using
anti-P2X7 receptor (extracellular) antibody, a signal which
was absent in the same cells from KO mice. In addition,
P2X7 was expressed in MC3T3-E1 osteoblasts and MLO-
Y4 osteocytes where it is activated following mechanical
load, leading to prostaglandin release from these cells and
the subsequent bone formation [80]. P2X7 expression was
also confirmed in synoviocytes from rheumatoid arthritis
patients by Western blot analysis. Pharmacological activa-
tion of P2X7 in these joint cells leads to increased IL-6
secretion, suggesting a role for P2X7 in a pro-inflammatory
pathway [69].
P2X7 was also reported to be expressed in skeletal
muscle cells: In mouse myotubes in culture, P2X7 immu-
noreactivity was confirmed by immunocytochemistry and
Western blot analyses; it was shown that the P2X7 signal is
significantly reduced following specific siRNA treatment.
Combining these results with functional studies, it is
suggested that the activation of ionotropic P2X4, P2X5,
and P2X7 and metabotropic P2Y1 and P2Y4 receptors
participates in forming the calcium transients of multinu-
cleated myotubes [89].
Inpancreaticcancerandchronicpancreatitispatients,some
evidence for P2X7 upregulation is observed in comparison to
normal pancreas. This upregulation was statistically signifi-
cant in RT-PCR experiments, but not in comparative Western
blot or immunohistochemical analyses. A detailed examina-
tion of immunohistochemistry experiments demonstrated
that most of the P2X7 immunoreactivity arises from staining
of immune system-infiltrating cells and was absent from
parenchymal cells [90]. In the insulinoma cell line INS-1e,
P2X7 expression was detected by Western blot analysis
(which was in correlation to mRNA levels), which increased
following P2X7 agonist application. However, P2X7 recep-
tors are probably not involved in insulin secretion or
apoptosis induction in these cells [91].
Recently, a novel P2X7 splice variant (P2X7k) with an
alternative first transmembrane domain was discovered.
Interestingly, this splice variant escapes gene inactivation in
KO mice, and its expression in different tissues (including
brain) of both wild-type and P2X7 KO mice was confirmed
using specific RT-PCR primers. In addition, at the protein
level, its expression was confirmed using Western blot
analysis in spleen, salivary gland, and lung from wild-type
mice as well as in the spleen of KO mice [73].
Ionotropic and matabotropic purinoceptors have indeed
proven to be most important in various biochemical and
physiological processes, as pointed out in the above
examples. Importantly, the pharmacological tools that have
been used to unravel these important receptors are
nowadays being coupled to antibodies. Indeed, the above
examples have also strongly shown that purinoceptor-
targeted small molecules and antibodies are intertwined in
revealing the localization and function of these receptors.
Commercially available antibodies provided by Alomone
Labs are undeniably valuable tools in understanding and
deciphering the specific purinergic receptor subtype in-
volved, a task that most pharmacological tools has yet to
show. The anti-P2Y receptor and the anti-P2X receptor
antibodies enable the detection of the various receptors via
Western blot analysis, immunohistochemistry, immunocy-
tochemistry, as well as indirect or direct flow cytometry.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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